A recent pan-Indian study published on November 18, 2026, in the Proceedings of the National Academy of Sciences highlights the potential of CancerSpot, a blood test developed by Bengaluru-based Strand Life Sciences, to improve early cancer detection. This non-invasive test analyzes cell-free DNA methylation patterns using advanced DNA sequencing and artificial intelligence to identify cancer-related changes.
Understanding CancerSpot and Its Technology
CancerSpot is designed to detect cancer by examining epigenetic changes—specifically DNA methylation—that do not alter the DNA sequence but affect gene activity. In cancer cells, abnormal methylation patterns can silence critical genes, contributing to tumor development. By analyzing these methylation signatures in cell-free DNA circulating in the blood, CancerSpot can detect cancer signals and even suggest the tissue of origin.
Cell-free DNA in healthy individuals mainly comes from blood cells, which creates a background noise for cancer detection. However, the test’s AI algorithms differentiate cancer-specific methylation patterns from this background, improving accuracy. This approach allows the detection of 14 different cancer types through a simple blood draw, offering a less invasive alternative to traditional diagnostic methods.
Key Findings from the Pan-Indian Study
- The study spanned four years and included 1,480 participants from 43 hospitals across India, comprising 950 cancer patients and 450 healthy volunteers.
- CancerSpot detected cancer in 72% of cases overall, with a low false-positive rate of 1.4%.
- Sensitivity varied by cancer stage: 79.3% for Stage I, 78.4% for Stage II and III, and 86.8% for Stage IV.
- Higher levels of circulating cell-free DNA, including from white blood cells, correlated with stronger cancer signals and better detection sensitivity.
These results demonstrate CancerSpot’s promise in identifying cancer early, even before symptoms appear, which is crucial for improving treatment outcomes.
Implications for Cancer Screening and Accessibility
Strand Life Sciences CEO Ramesh Hariharan emphasized in 2024 that the test aims to detect cancer at its earliest stages, potentially transforming cancer screening practices. Currently priced at approximately ₹22,000, the company plans to reduce the cost to around ₹10,000 within two to three years, making it more accessible to a broader population.
Early detection through such blood tests could reduce reliance on invasive biopsies and imaging, enabling timely interventions and better survival rates. The study’s success also encourages further research into integrating AI and epigenetics for cancer diagnostics.
Frequently Asked Questions
Q: What is DNA methylation and why is it important in cancer detection?
A: DNA methylation is a chemical modification that can turn genes on or off without changing the DNA sequence. Abnormal methylation patterns are common in cancer cells and can be used as markers to detect cancer early.
Q: How accurate is the CancerSpot test?
A: The test detected cancer in 72% of cases overall, with sensitivities ranging from about 79% in early stages to nearly 87% in advanced stages, and a low false-positive rate of 1.4%.
Q: When will CancerSpot become more affordable?
A: Strand Life Sciences plans to reduce the test’s price from around ₹22,000 to approximately ₹10,000 within two to three years, aiming to make it accessible to more people.

